GLP1R and metabolic dysfunction-associated steatotic liver disease: There is an association between NAFLD and metabolic syndrome that causes DM, dyslipidemia, and obesity suggesting that breaking this cycle by GLP-1 agonists may have therapeutic potential [18], particularly as they may have anti-inflammation activity [19].